975 articles in this topic
A lab study finds ACU193 binds less to brain blood vessels than lecanemab, potentially explaining differences in ARIA side effect risk.
A narrative review reveals India's unique dementia risk profile — and why Western findings may not apply to 1.4 billion people.
In CADASIL patients, MRI-derived brain age runs years ahead of chronological age, tracking disease severity and cognitive decline.
A 12-month Emory trial tests partnered rhythmic dance vs. walking to protect motor-cognitive function in prodromal Alzheimer's patients.
A pilot trial tests whether group and phone-based CBT can sharpen cognition and cut chronic stress in African Americans at risk for Alzheimer's.
A VA-sponsored trial tested whether the blood pressure drug prazosin could remove toxic proteins linked to CTE and Alzheimer's in combat veterans.
New research positions sleep EEG as an early biomarker for future neurological decline, offering a non-invasive window into brain aging.
A Mayo Clinic study reveals the Lumipulse p-tau217/Aβ42 plasma ratio has variable accuracy in detecting Alzheimer's amyloid pathology.
New research reveals DBS doesn't just stimulate neurons — it physically remodels white matter and reshapes brain-wide connectivity.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
Synthetic peptide chimeras degrade amyloid-beta across the blood-brain barrier, improving cognition in mice with fewer risks than current immunotherapies.
A 2-year-old's puzzling eye paralysis pattern reveals an extraordinarily rare congenital wiring error in the oculomotor nerve.
